Abstract
Protein kinases play central roles in cellular signaling pathways and their abnormal phosphorylation activity is inseparably linked with various human diseases. Therefore, modulation of kinase activity using potent inhibitors is an attractive strategy for the treatment of human disease. While most protein kinase inhibitors in clinical development are mainly targeted to the highly conserved ATP-binding sites and thus likely promiscuously inhibit multiple kinases including kinases unrelated to diseases, protein substratecompetitive inhibitors are more selective and expected to be promising therapeutic agents. Most substrate-competitive inhibitors mimic peptides derived from substrate proteins, or from inhibitory domains within kinases or inhibitor proteins. In addition, bisubstrate inhibitors are generated by conjugating substrate-competitive peptide inhibitors to ATP-competitive inhibitors to improve affinity and selectivity. Although structural information on protein kinases provides invaluable guidance in designing substrate-competitive inhibitors, other strategies including bioinformatics, computational modeling, and high-throughput screening are often employed for developing specific substrate-competitive kinase inhibitors. This review focuses on recent advances in the design and discovery of substrate-competitive inhibitors of protein kinases.
Keywords: Protein kinase, inhibitor, substrate-competitive, peptide, bisubstrate, phosphorylation, ATP-binding sites, GSK-3, Src, proteases
Current Pharmaceutical Design
Title:Recent Advances in Designing Substrate-Competitive Protein Kinase Inhibitors
Volume: 18 Issue: 20
Author(s): Ki-Cheol Han, So Yeon Kim and Eun Gyeong Yang
Affiliation:
Keywords: Protein kinase, inhibitor, substrate-competitive, peptide, bisubstrate, phosphorylation, ATP-binding sites, GSK-3, Src, proteases
Abstract: Protein kinases play central roles in cellular signaling pathways and their abnormal phosphorylation activity is inseparably linked with various human diseases. Therefore, modulation of kinase activity using potent inhibitors is an attractive strategy for the treatment of human disease. While most protein kinase inhibitors in clinical development are mainly targeted to the highly conserved ATP-binding sites and thus likely promiscuously inhibit multiple kinases including kinases unrelated to diseases, protein substratecompetitive inhibitors are more selective and expected to be promising therapeutic agents. Most substrate-competitive inhibitors mimic peptides derived from substrate proteins, or from inhibitory domains within kinases or inhibitor proteins. In addition, bisubstrate inhibitors are generated by conjugating substrate-competitive peptide inhibitors to ATP-competitive inhibitors to improve affinity and selectivity. Although structural information on protein kinases provides invaluable guidance in designing substrate-competitive inhibitors, other strategies including bioinformatics, computational modeling, and high-throughput screening are often employed for developing specific substrate-competitive kinase inhibitors. This review focuses on recent advances in the design and discovery of substrate-competitive inhibitors of protein kinases.
Export Options
About this article
Cite this article as:
Han Ki-Cheol, Yeon Kim So and Gyeong Yang Eun, Recent Advances in Designing Substrate-Competitive Protein Kinase Inhibitors, Current Pharmaceutical Design 2012; 18 (20) . https://dx.doi.org/10.2174/138161212800672697
DOI https://dx.doi.org/10.2174/138161212800672697 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Strategies for the Preparation of Bifunctional Gadolinium(III) Chelators
Current Organic Synthesis Reversing Agents for ATP-Binding Cassette (ABC) Transporters: Application in Modulating Multidrug Resistance (MDR)
Current Medicinal Chemistry - Anti-Cancer Agents Cause and Consequences of Genetic and Epigenetic Alterations in Human Cancer
Current Genomics Animal Modeling of Cancer Pathology and Studying Tumor Response to Therapy
Current Drug Targets Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System
Current Cancer Drug Targets Dual Acting Anti-Inflammatory Drugs
Current Topics in Medicinal Chemistry Isothiocyanates in the Chemoprevention of Bladder Cancer
Current Drug Metabolism Combating Diseases with Computational Strategies Used for Drug Design and Discovery
Current Topics in Medicinal Chemistry The Innate Immunity in Alzheimer Disease- Relevance to Pathogenesis and Therapy
Current Pharmaceutical Design Targeting the Wingless Signaling Pathway with Natural Compounds as Chemopreventive or Chemotherapeutic Agents
Current Pharmaceutical Biotechnology The Relation Between Stereochemistry and Biological Activity of Platinum(II) Complexes Chelated with Chiral Diamine Ligands: An Intricate Problem
Current Pharmaceutical Design 4-Aminoquinazoline Analogs: A Novel Class of Anticancer Agents
Mini-Reviews in Medicinal Chemistry Application of NMR Metabolomics to Search for Human Disease Biomarkers
Combinatorial Chemistry & High Throughput Screening A Comparative Study of the Cytotoxic and Pro-apoptotic Properties of Nepeta binaloudensis
Letters in Drug Design & Discovery Importance of Male Fertility Control in Family Planning
Endocrine, Metabolic & Immune Disorders - Drug Targets Mechanisms for Targeted Delivery of Nanoparticles in Cancer
Current Pharmaceutical Design Synthetic Androgens as Designer Supplements
Current Neuropharmacology Microwave-assisted Extraction Coupled with High Performance Liquid Chromatography-electrospray Ion Trap Mass Spectrometry for the Determination of Three Flavone di-C-glycosides in Viola yedoensis
Current Analytical Chemistry Comparative Study of Growth Hormone Treatment in Children with Idiopathic Short Stature and Growth Hormone Deficiency
Current Drug Metabolism Generating Recombinant Antibodies for Research, Diagnostics and Therapy Using Phage Display
Current Biotechnology